The relationship between anxiety and serum Urotensin-II and S100B levels in patients with essential hypertension
Yıl: 2021 Cilt: 24 Sayı: 3 Sayfa Aralığı: 315 - 323 Metin Dili: İngilizce DOI: 10.5505/kpd.2021.67044 İndeks Tarihi: 09-11-2021
The relationship between anxiety and serum Urotensin-II and S100B levels in patients with essential hypertension
Öz: Objective: In hypertensive people, some biochemicalparameters that are associated with oxidative stress andendothelial functions may play a role in the manifestation of anxiety symptoms, and even in the intensificationof clinical symptoms of the disease. The purpose of ourcorrelative study is to examine the association betweenanxiety severity and levels of oxidative stress parametersof Urotensin-II and S100B protein in patients with essential hypertension. Method: A total of 153 patients, whohave applied Sociodemographic and Clinical Data Form,Beck Anxiety Inventory (BAI), Beck Depression Inventoryand venous blood samples were taken after blood pressure measurement. S100B and Urotensin-II levels weremeasured with Enzyme-Linked Immunosorbent Assaymethod. Results: A positive correlation was determinedbetween depression and anxiety scores, and systolicblood pressure (p=0.049, r= 0.160; p<0.01, r=0.292).There was a positive relation between BAI scores andUrotensin-II levels (p= 0.043, r= 0.164). A positive correlation was determined between Urotensin-II levels andS100B levels (p<0.01, r= 0.711). A statistically significant difference was observed in serum Urotensin-II levelsbetween depression group and no depression group(p=0.017). Discussion: It was determined in our studythat Urotensin-II level increased with increasing anxietylevel in essential hypertension patients. It was also determined that Urotensin-II level was higher in hypertensivepatients with depression compared to patients whodon't have depression. Our study will shed light on newstudies that will investigate the contribution ofUrotensin- II and S100B in the etiology of patients diagnosed with essential hypertension, which is very commonly accompanied by anxiety and depressive symptoms.
Anahtar Kelime: Esansiyel hipertansiyonlu hastalarda anksiyete ile serum ürotensin-II ve S100B seviyeleri arasındaki ilişki
Öz: Amaç: Hipertansiyonlu bireylerde anksiyete bulgularının ortaya çıkmasında hatta hastalığın klinik bulgularının şiddetlenmesinde oksidatif stresle ve endotel fonksiyonlarıyla ilişkili olan bazı biyokimyasal parametrelerin rolü olabilir. Çalışmamızda, esansiyel hipertansiyon hastalarının anksiyete düzeyleri araştırılarak, anksiyete şiddetinin oksidatif stres parametrelerinden olan Ürotensin-II ve S100B protein seviyeleri üzerindeki etkisinin incelenmesi amaçlanmıştır. Yöntem: Çalışmaya, kan basıncı ölçümleri sonrasında venöz kan örnekleri alınan ve Sosyodemografik ve Klinik Veri Formu, Beck Anksiyete Ölçeği (BAÖ), Beck Depresyon Ölçeği (BDÖ) ölçekleri uygulanan 153 hasta dahil edildi. EnzymeLinked Immunosorbent Assay (ELISA) yöntemi ile S100B ve Ürotensin-II düzeyleri ölçüldü. Bulgular: Depresyon ve anksiyete puanları ile sistolik kan basıncı arasında pozitif yönde bir korelasyon bulunmaktaydı (p=0.049, r= 0.160; p<0.01, r=0.292). Hastaların BAÖ puanları ile Ürotensin-II seviyeleri arasında pozitif bir ilişki bulunmaktaydı (p= 0.043, r= 0.164). Ürotensin-II seviyeleri ile S100B seviyeleri arasında pozitif yönde korelasyon izlendi (p<0.01, r= 0,711). Hastalardan depresyonu olan grupla, olmayan grubun serum Ürotensin-II seviyeleri arasında istatiksel olarak anlamlı fark gözlendi (p=0.017). Sonuç: Çalışmamızda esansiyel hipertansiyonlu hastalarda anksiyete düzeyleri arttıkça Ürotensin-II seviyesinin arttığı tespit edilmiştir. Yine Ürotensin-II ’nin, depresyonu olan hipertansif hastalarda depresyonu olmayanlara göre daha yüksek olduğu belirlenmiştir. Çalışmamız anksiyete ve depresif semptomların çok sık eşlik ettiği esansiyel hipertansiyon tanılı hastalarda Ürotensin- II ve S100B ‘nin etiyolojiye olabilecek katkısının araştırılacağı yeni çalışmalara ışık tutacaktır
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Ewald DR, Haldeman LA. Risk Factors in Adolescent Hypertension. Glob Pediatr Health 2016; 3: 2333794X15625159.
- 2. Özen EM, Serhadlı ZN, Türkcan AS, Ülker GE. Somatization in Depression and Anxiety Disorders. The Journal of Psychiatry and Neurological Sciences 2010; 23:60-65.
- 3. Liu MY, Li N, Li WA, Khan H. Association between psychosocial stress and hypertension: a systematic review and metaanalysis. Neurol. Res 2017; 39: 573–580. doi: 10.1080/01616412.2017.1317904
- 4. McDonald J, Batuwangala M, Lambert DG. Role of urotensin II and its receptor in health and disease. J Anesth 2007; 21: 378–389.
- 5. Tabur S, Korkmaz H, Eren MA, Oğuz E, Sabuncu T, Aksoy N. Urotensin-II level and its association with oxidative stress in early diabetic nephropathy. J Diabetes Complications 2015; 29(1):115-119.
- 6. Jégou S, Cartier D, Dubessy C, Gonzalez BJ, Chatenet D, Tostivint H, Scalbert E, LePrince J, Vaudry H, Lihrmann I. Localization of the urotensin II receptor in the rat central nervous system. J Comp Neurol 2006; 495:21–36.
- 7. Adami C, Sorci G, Blasi E, Agneletti AL, Bistoni F, Donato R. S100B expression in and effects on microglia. Glia 2001; 33:131–142.
- 8. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37:2129-2200.
- 9. Beck AT, Steer RA, Brown GK, Gregory KB. "Manual for the beck depression inventory-II. San Antonio, TX: Psychological Corporation 1996; 82.
- 10. Beck AT, Epstein N, Brown G, Ster RA. An inventory for measuring clinical anxiety: psychometric properties. J Consul Clin Psychol 1988; 56:893-897.
- 11. Ulusoy M, Sahin NH, Erkmen H. Turkish version of the Beck anxiety inventory: psychometric Properties. J Cogn Psychother Int Q 1998; 12: 163-172.
- 12. Hisli N. Beck depresyon envanterinin üniversite öğrencileri için geçerliği, güvenirliği. Psikoloji Dergisi 1989; 7-13.
- 13. Peng H, Zhang M, Cai X, Olofindayo J, Tan A, Zhang Y. Association between human urotensin II and essential hypertension-a 1:1 matched case-control study. PloS One 2013; 8(12): 81764. https://doi: 10.1371/journal.pone.0081764.
- 14. Djordjevic T, BelAiba RS, Bonello S, Pfeilschifter J, Hess J, Görlach, Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arteriosclerosis, thrombosis, and vascular biology 2005; 25(3): 519- 525.
- 15. Watson AM, May CN. Urotensin II, a novel peptide in central and peripheral cardiovascular control. Peptides 2004; 25:1759–1766.
- 16. Sugo T, Murakami Y, Shimomura Y, Harada M, Abe M, Ishibashi Y, Kitada C, Miyajima N, Suzuki N, Mori M, Fujino M. Identification of urotensin II-related peptide as the urotensin II immunoreactive molecule in the rat brain. Biochem Biophys Res Commun 2003; 310:860-868.
- 17. Gao S, Oh YB, Park BM, Park WH, Kim SH. Urotensin II protects ischemic reperfusion injury of hearts through ROS and antioxidant pathway. Peptides 2012; 36(2):199-205. doi: 10.1016/j.peptides.2012.05.004. Epub 2012 May 15.
- 18. Liu MY, Li N, Li WA, Khan H. Association between psychosocial stress and hypertension: a systematic review and metaanalysis. Neurol Res 2017; 39: 573–580. doi: 10.1080/01616412.2017.1317904.
- 19. Ginty AT, Carroll D, Roseboom TJ, Phillips AC, De Rooij SR. Depression and anxiety are associated with a diagnosis of hypertension 5 years later in a cohort of late middle-aged men and women. J Hum Hypertens 2013; 27: 187–190. doi: 10.1038/jhh.2012.18
- 20. Matsumoto Y, Abe M, Watanabe T, Adachi Y, Yano T, Takahashi H, Sugo T, Mori M, Kitada C, Kurokawa T, Fujino M. Intracerebroventricular administration of urotensin II promotes anxiogenic-like behaviors in rodents. Neurosci Lett 2004; 358: 99–102.
- 21. Watson AM, May CN. Urotensin II, a novel peptide in central and peripheral cardiovascular control. Peptides 2004; 25: 1759 – 1766.
- 22. Kawaguchi Y, Ono T, Kudo M, Kushikata T, Hashiba E, Yoshida H, Kudo T, Furukawa K, Douglas SA, Hirota K. The Effects of Benzodiazepines on Urotensin II Stimulated Norepinephrine Release from Rat Cerebrocortical Slices. Anesth Analg 2009; 108(4): 1177-1181. doi: 10.1213/ane.0b013e3181981faa.
- 23. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008; 21: 1-26.
- 24. Hunt BD, Leong LN, Lambert DG. A rat brain atlas of urotensin-II receptor expression and a review of central urotensin-II effects. Naunyn-Schmied Arch Pharmacol 2010; 382: 1–31.
- 25. Bulut M, Selek S, Bez Y, Karababa FI, Kaya MC, Gunes M, Emhan A, Aksoy N, Sir A. Reduced PON1 enzymatic activity and increased lipid hydroperoxide levels that point out oxidative stress in generalized anxiety disorder. J Affect Disord 2013; 150: 829–833.
- 26. Ozdemir O, Selvi Y, Ozkol H, Tuluce Y, Besiroglu L, Aydin A. Comparison of superoxide dismutase, glutathione peroxidase and adenosine deaminase activities between respiratory and nocturnal subtypes of patients with panic disorder. Neuropsychobiology 2012; 66: 244–51.
- 27. Ersan S, Bakir S, Ersan EE, Dogan O. Examination of free radical metabolism and antioxidant defence system elements in patients with obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1039–1042.
- 28. Hovatta I, Tennant RS, Helton R, Marr RA, Singer O, Redwine JM, Ellison JA, Schadt EE, Verma IM, Lockhart DJ, Barlow C. Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. Nature 2005; 38: 662–666.
- 29. Bouayed J, Rammal H, Younos C, Soulimani R. Positive correlation between peripheral blood granulocyte oxidative status and level of anxiety in mice. Eur J Pharmacol 2007; 564: 146– 149.
- 30. Calvo DJ, González AN. Dynamic regulation of the GABAA receptor function by redox mechanisms. Mol Pharmacol 2016; 90: 326–333.
- 31. Bülbül F, Alpak G, Ünal A, Cöpoğlu S, Orkmez M, Virit O, Savas HA. New molecule in the etiology of schizophrenia: Urotensin II. Psych Clin Neuro Sci 2014; 68 (2): 133–136.
- 32. da Rosa MI, Simon C, Grande AJ, Barichello T, Oses JP, Quevedo J. Serum S100B in manic bipolar disorder patients: systematic review and meta-analysis. J Affect Disord 2016; 206: 210–215.
- 33. Schroeter ML, Steiner J, Schonknecht P. Further evidence for a role of S100B in mood disorders: a human gene expression mega-analysis. J Psychiatr Res 2014; 53: 84–86.
- 34. Villarreal A, Seoane R, Torres AG, Rosciszewski G, Angelo MF, Rossi A, Barker PA, Ramos AJ. S100B protein activates a RAGE-dependent autocrine loop in astrocytes: Implications for Its role in the propagation of reactive gliosis. J Neurochem 2014; 131: 190-205.
- 35. Kroksmark H, Vinberg M. Does S100B have a potential role in affective disorders? A literature review. Nordic Journal of Psychiatry 2018; 72:462-470.
- 36. Ritthaler U, Deng Y, Zhang Y, Greten J, Abel M, Sido B. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol 1995; 146: 688.
- 37. Jang BS, Kim H, Lim SW, Jang KW, Kim DK. Serum S100B levels and majör depressive disorder: its characteristics and role in antidepressant response. Psychiatry Investig; 2008; 5:193–198.
- 38. Schroeter ML, Abdul-Khaliq H, Diefenbacher A, Blasig IE. S100B is increased in mood disorders and may be reduced by antidepressive treatment. Neuroreport 2002; 13: 1675–1678.
- 39. Arolt V, Peters M, Erfurth A, Wiesmann M, Missler U, Rudolf S, Rothermundt M. S100B and response to treatment in major depression: a pilot study. Eur Neuropsychopharmacol 2003; 13: 235–239.
- 40. Hetzel G, Moeller O, Evers S, Erfurth A, Ponath G, Arolt V, Rothermundt M. The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment. Psychopharmacology 2005; 178(2-3): 161–166.
- 41. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE. Serum markers support disease-specific glial pathology in major depression. J Affect Disord 2008; 111: 271–280.
- 42. Tsai MC, Huang TL. Increased activities of both superoxide dismutase and catalase were indicators of acute depressive episodes in patients with major depressive disorder. Psychiatry Res 2016; 235: 38–42.
- 43. Fang Y, Xiao SF, Zhang SY, Qiu Q, Wang T, Li X. Increased plasma S100b level in patients with major depressive disorder. CNS Neurosci Ther 2016; 22: 248–250.
- 44. Rothermundt M, Arolt V, Wiesmann M, Missler U, Peters M, Rudolf S, Kirchner H. S-100B is increased in melancholic but not in non-melancholic major depression. J Affect Disord 2001; 66: 89–93.
| APA | Kazğan Kılıçaslan A, KORKMAZ S, Yildiz S, KORKMAZ H, TELO S, Atmaca M (2021). The relationship between anxiety and serum Urotensin-II and S100B levels in patients with essential hypertension. , 315 - 323. 10.5505/kpd.2021.67044 |
| Chicago | Kazğan Kılıçaslan Aslı,KORKMAZ SEVDA,Yildiz Sevler,KORKMAZ HASAN,TELO Selda,Atmaca Murad The relationship between anxiety and serum Urotensin-II and S100B levels in patients with essential hypertension. (2021): 315 - 323. 10.5505/kpd.2021.67044 |
| MLA | Kazğan Kılıçaslan Aslı,KORKMAZ SEVDA,Yildiz Sevler,KORKMAZ HASAN,TELO Selda,Atmaca Murad The relationship between anxiety and serum Urotensin-II and S100B levels in patients with essential hypertension. , 2021, ss.315 - 323. 10.5505/kpd.2021.67044 |
| AMA | Kazğan Kılıçaslan A,KORKMAZ S,Yildiz S,KORKMAZ H,TELO S,Atmaca M The relationship between anxiety and serum Urotensin-II and S100B levels in patients with essential hypertension. . 2021; 315 - 323. 10.5505/kpd.2021.67044 |
| Vancouver | Kazğan Kılıçaslan A,KORKMAZ S,Yildiz S,KORKMAZ H,TELO S,Atmaca M The relationship between anxiety and serum Urotensin-II and S100B levels in patients with essential hypertension. . 2021; 315 - 323. 10.5505/kpd.2021.67044 |
| IEEE | Kazğan Kılıçaslan A,KORKMAZ S,Yildiz S,KORKMAZ H,TELO S,Atmaca M "The relationship between anxiety and serum Urotensin-II and S100B levels in patients with essential hypertension." , ss.315 - 323, 2021. 10.5505/kpd.2021.67044 |
| ISNAD | Kazğan Kılıçaslan, Aslı vd. "The relationship between anxiety and serum Urotensin-II and S100B levels in patients with essential hypertension". (2021), 315-323. https://doi.org/10.5505/kpd.2021.67044 |
| APA | Kazğan Kılıçaslan A, KORKMAZ S, Yildiz S, KORKMAZ H, TELO S, Atmaca M (2021). The relationship between anxiety and serum Urotensin-II and S100B levels in patients with essential hypertension. Klinik Psikiyatri Dergisi, 24(3), 315 - 323. 10.5505/kpd.2021.67044 |
| Chicago | Kazğan Kılıçaslan Aslı,KORKMAZ SEVDA,Yildiz Sevler,KORKMAZ HASAN,TELO Selda,Atmaca Murad The relationship between anxiety and serum Urotensin-II and S100B levels in patients with essential hypertension. Klinik Psikiyatri Dergisi 24, no.3 (2021): 315 - 323. 10.5505/kpd.2021.67044 |
| MLA | Kazğan Kılıçaslan Aslı,KORKMAZ SEVDA,Yildiz Sevler,KORKMAZ HASAN,TELO Selda,Atmaca Murad The relationship between anxiety and serum Urotensin-II and S100B levels in patients with essential hypertension. Klinik Psikiyatri Dergisi, vol.24, no.3, 2021, ss.315 - 323. 10.5505/kpd.2021.67044 |
| AMA | Kazğan Kılıçaslan A,KORKMAZ S,Yildiz S,KORKMAZ H,TELO S,Atmaca M The relationship between anxiety and serum Urotensin-II and S100B levels in patients with essential hypertension. Klinik Psikiyatri Dergisi. 2021; 24(3): 315 - 323. 10.5505/kpd.2021.67044 |
| Vancouver | Kazğan Kılıçaslan A,KORKMAZ S,Yildiz S,KORKMAZ H,TELO S,Atmaca M The relationship between anxiety and serum Urotensin-II and S100B levels in patients with essential hypertension. Klinik Psikiyatri Dergisi. 2021; 24(3): 315 - 323. 10.5505/kpd.2021.67044 |
| IEEE | Kazğan Kılıçaslan A,KORKMAZ S,Yildiz S,KORKMAZ H,TELO S,Atmaca M "The relationship between anxiety and serum Urotensin-II and S100B levels in patients with essential hypertension." Klinik Psikiyatri Dergisi, 24, ss.315 - 323, 2021. 10.5505/kpd.2021.67044 |
| ISNAD | Kazğan Kılıçaslan, Aslı vd. "The relationship between anxiety and serum Urotensin-II and S100B levels in patients with essential hypertension". Klinik Psikiyatri Dergisi 24/3 (2021), 315-323. https://doi.org/10.5505/kpd.2021.67044 |
